Published in J Prev Alzheimers Dis on June 01, 2015
Use of High-Frequency In-Home Monitoring Data May Reduce Sample Sizes Needed in Clinical Trials. PLoS One (2015) 0.83
Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire. Alzheimers Dement (Amst) (2017) 0.75
A Systematic Review of Intervention Studies Examining Nutritional and Herbal Therapies for Mild Cognitive Impairment and Dementia Using Neuroimaging Methods: Study Characteristics and Intervention Efficacy. Evid Based Complement Alternat Med (2017) 0.75
Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Readying for Short-term and Long-term Clinical Trial Needs. Innov Clin Neurosci (2017) 0.75
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 21.80
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.67
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.50
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol (2013) 5.73
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol (2014) 5.61
The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol (2010) 4.59
3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. Brain (2007) 3.53
Impaired financial abilities in mild cognitive impairment: a direct assessment approach. Neurology (2003) 2.97
Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis (2011) 2.78
Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol (2012) 2.61
Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther (2011) 2.51
Assessing financial capacity in patients with Alzheimer disease: A conceptual model and prototype instrument. Arch Neurol (2000) 2.17
Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1-42. Ann Neurol (2010) 2.15
The preclinical Alzheimer cognitive composite: measuring amyloid-related decline. JAMA Neurol (2014) 1.96
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Declining financial capacity in mild cognitive impairment: A 1-year longitudinal study. Neurology (2009) 1.69
Biomarkers in Alzheimer's disease drug development. Nat Med (2010) 1.61
Dominantly Inherited Alzheimer Network: facilitating research and clinical trials. Alzheimers Res Ther (2013) 1.44
Neurocognitive predictors of financial capacity across the dementia spectrum: Normal aging, mild cognitive impairment, and Alzheimer's disease. J Int Neuropsychol Soc (2009) 1.39
Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease. Alzheimers Dement (2013) 1.38
The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron (2014) 1.35
Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial. Rev Neurol (Paris) (2013) 1.33
Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimers Dement (2014) 1.31
Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. Alzheimers Dement (2014) 1.28
An empirically derived composite cognitive test score with improved power to track and evaluate treatments for preclinical Alzheimer's disease. Alzheimers Dement (2014) 1.26
The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers. J Clin Psychiatry (2014) 1.25
Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study. JAMA Neurol (2015) 1.23
Immunoelectron microscopic study of synaptic pathology in Alzheimer's disease. Acta Neuropathol (1991) 1.20
Neurochemical dissection of synaptic pathology in Alzheimer's disease. Int Psychogeriatr (1998) 1.18
The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials. Alzheimers Dement (2012) 1.16
The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity. Alzheimers Dement (2014) 1.16
Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid. Acta Neuropathol (2013) 1.11
Activities of daily living: where do they fit in the diagnosis of Alzheimer's disease? Neurodegener Dis Manag (2012) 1.08
Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimers Dement (2012) 1.07
A concise radiosynthesis of the tau radiopharmaceutical, [(18) F]T807. J Labelled Comp Radiopharm (2013) 1.03
Magnetic resonance imaging volume of the angular gyri predicts financial skill deficits in people with amnestic mild cognitive impairment. J Am Geriatr Soc (2010) 0.98
Assessing cognition and function in Alzheimer's disease clinical trials: do we have the right tools? Alzheimers Dement (2014) 0.97
Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia. J Alzheimers Dis (2015) 0.96
Tracking early decline in cognitive function in older individuals at risk for Alzheimer disease dementia: the Alzheimer's Disease Cooperative Study Cognitive Function Instrument. JAMA Neurol (2015) 0.95
Longitudinal trajectories of everyday function by diagnostic status. Psychol Aging (2013) 0.94
Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-β in cerebrospinal fluid. Clin Chem (2014) 0.87
Charting a path toward combination therapy for Alzheimer's disease. Expert Rev Neurother (2014) 0.87
MRI volume of the medial frontal cortex predicts financial capacity in patients with mild Alzheimer's disease. Brain Imaging Behav (2013) 0.86
Qualification of a surrogate matrix-based absolute quantification method for amyloid-β₄₂ in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry. J Alzheimers Dis (2014) 0.82
Establishing the psychometric underpinning of cognition measures for clinical trials of Alzheimer's disease and its precursors: a new approach. Alzheimers Dement (2013) 0.78
Development of a straightforward and sensitive scale for MCI and early AD clinical trials. Alzheimers Dement (2014) 0.77
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17
Progress in Treatment Development for Neuropsychiatric Symptoms in Alzheimer's Disease: Focus on Agitation and Aggression. A Report from the EU/US/CTAD Task Force. J Prev Alzheimers Dis (2015) 0.75
Policy agenda for nurse-led care coordination. Nurs Outlook (2015) 0.75